NCT04688008View on ClinicalTrials.gov

Relative Bioavailability of Early Phase and Late Phase Hetrombopag Olamine Formulations

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

September 18, 2020

Primary Completion Date

October 12, 2020

Study Completion Date

October 30, 2020

Conditions
Bioavailability Study
Interventions
DRUG

Hetrombopag

"Drug: Early phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions~Drug: Late phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions"

Trial Locations (1)

Unknown

The Second Hospital of Anhui Medical University, Hefei

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04688008 - Relative Bioavailability of Early Phase and Late Phase Hetrombopag Olamine Formulations | Biotech Hunter | Biotech Hunter